Argus downgraded Regeneron Pharmaceuticals from a buy to a hold rating in its latest research report, signaling caution.

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

ROCHESTER, Minn. (KTTC) – A Winona industrial supply company provided assistance to a Wisconsin high school student’s science ...

FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial.

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

Najpierw wprowadzenie podatku akcyzowego na saszetki nikotynowe, potem propozycja przepisów, które zmierzają do wycofania tych produktów z rynku – przedstawiciele środowisk ...

"Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma" was originally created and published by ...

The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires.

The reinstatement of two soccer bribery convictions, President Trump's asylum ban being blocked, FDA's approval of ...

A federal bankruptcy court this week approved the sale of 23andMe to TTAM Research Institute - a new company launched by ...